Search Results

Biophytis SA announces the implementation of a dedicated strategy for partner search in obesity.

Biophytis SA announces the design of its phase 2 OBA clinical study in obesity with BIO101.

Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the successful transfer of BIO101 production to industrial scale by Seqens.

Biophytis SA announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 in Latin American including, but not limited to Brazil, Mexico, Argentina and Colombia.

Biophytis SA announced that on April 24, 2024, the Company received formal notice from The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel had determined to delist the Company’s American Depositary Shares from The Nasdaq Capital Market based upon the Company’s non-compliance with the stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550.

Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”) today announces that it is launching a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity in combination with GLP-1 receptor agonists.